NCT07423312Not yet recruiting
Lead Exposure and Multiple Sclerosis
Lead Exposure and Multiple Sclerosis;Biomarker Evidance and Clinical Impact.
Source: ClinicalTrials.gov · Last updated 20 Feb 2026
Brief summary (registry, in English)
1. To evaluate the effect of lead level on the pathogenesis of multiple sclerosis 2. Measure lead in blood sample of study groups 3. Estimate the expression level of DNA methyltransferase. 4. Evaluate oxidative stress markers, like MDA/8-OHdG 5. Measureδ-aminolevulinic acid 6. Correlate the clinical data of patients with biochemical markers
- Status (registry)
- Not yet recruiting
- Study type
- Observational
- Enrollment
- 140 (estimated)
- First submitted
- 11 Feb 2026
- Start date
- 30 Dec 2026
- Primary completion date
- 30 Dec 2028
- Lead sponsor
- Assiut University
- Diseases
- Multiple sclerosis
- NCT number
- NCT07423312
What you commit to
- Study type: Observational
- Planned participants: 140
- From 30 Dec 2026 to the primary completion date, 30 Dec 2028
- No sites listed in no country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other illness
- other autoimmune disease Chronic renal or liver disease
Who the study is looking for
- patients aged20-50 years diagnosed MS patients according to Mc Donald criteria
Age in the registry: 20 years to 50 years · Sex: All · Accepts healthy volunteers
This page is information, not medical advice. Discuss any trial with your doctor.